MarketVIEW: Dengue vaccines

• Publication date: January 2012
• Report size: 125 pages

Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs) where no specific treatment is available. ...

Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs) where no specific treatment is available.

This MarketVIEW product forecasts the potential commercial value of dengue fever vaccine(s) across endemic and travelers markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector. LO and HI forecast scenarios which include expected demand from country selected catch-up campaigns are also detailed along with discussion of development considerations of the ideal dengue vaccine(s) in light of current pipeline candidates.

THIS PRODUCT IS TWO EXECUTIVE PRESENTATIONS + TWO MODELS 

Drug And Medication Industry in Europe

Contents – Summary presentation (MS PowerPoint based)
Author’s note
Executive Summary
Commercial model – key outputs
Summary for total number of CDI cases (theoretical and treated) in Emerging + ROW region
2020 Snapshot CDI cases (theoretical)
Deploying C.diff vaccines: primary prevention (PX)
C.diff vaccines: three potential markets modelled
PX indication (community) – total predicted demand (doses 000s)
PX indication (community) – total available market ($ USD 000s)
PX indication (hospital admission) – total available market ($ USD 000s)
TX indication (hospital) – total predicted demand (doses 000s)
TX indication (hospital) – total available market ($ USD 000s)
C.diff vaccines: total commercial summary (peak)
C.diff vaccines – key model assumptions
C.diff vaccines – countries included in model
Community prophylaxis – major model assumptions
Prevention of CDI recurrences (TX) – major model assumptions
Hospital prophylaxis – major model assumptions
Primary research – summary of findings
C.diff (CDI) situation analysis
Primary research respondents
Expert viewpoints: nosocomial infections in general
Expert viewpoints: major pathogens
Expert viewpoints: reporting surveillance
Brazil: National Health Surveillance Agency (ANVISA)
Mexico: National Health Surveillance Agency (SALUD)
Expert viewpoints: nosocomial infections – incidence estimates
Expert viewpoints: awareness of Clostridium difficile
Expert viewpoints: is CDI a growing problem?
Expert viewpoints: test for Clostridium difficile
Expert viewpoints: C.diff molecular epidemiology
C.diff as a % of nosocomial diarrhea – Emerging markets/ROW region
Expert viewpoints: treating CDI
Country environment factors contributing to CDI
Expert viewpoints: (use) misuse of antibiotics
Expert viewpoints: role of hospitals (LOS)
Expert viewpoints: elderly care/the role of nursing homes
Other notable patient factors
Expert Reaction to C.diff R&D pipeline and vaccines
CDI pipeline: by estimated filing date
Expert viewpoints: CDI R&D pipeline (all)
Expert viewpoints: C.diff vaccines – general comments
Expert viewpoints: deploying C.diff vaccines
Expert viewpoints: funding C.diff vaccines
Back-up and source material
CDI – Western markets
Definition of at-risk population (community vaccination)
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Title sheet
CHARTS (PX) comm.
CHARTS (PX) hosp
CHARTS (TX)
CHARTS (Epi)
Val/Vol summary (PX comm)
Val/Vol summary (PX hosp)
Val/Vol summary (TX)
Vaccine pricing forecast
Epi summary – CDI
Prophylaxis (hosp admission)
All admissions (>65 yrs)
Emer admissions (>65yrs)
Elect admissions (>65yrs)
PX > 65yrs (comm) and TX (RD – first line)
Brazil
Russia
India
China
Argentina
Chile
Columbia
Venezuela
Turkey
Saudi Arabia
Poland
Czech Republic
Slovakia
Hungary
South Africa
Malaysia
Singapore
Indonesia
Philippines
Thailand
South Korea
Source material
Nosocomial diarrhea (CDIFF)
Hospital admissions forecast
Hospital beds – admissions
China – hospital statistics
Brazil – hospital statistics
Hospital beds (historical)
Hospital discharges (historical)
Population database (all ages)
Population database (65 – 90 yrs)
Hospital admission breakdown by type
Back-page
WORKSHEETS: ~65

Drug and Medication in Europe

Portugal Pharmaceutical Sales, Us$bn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Eurbn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales At Constant Exchange Rate, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Us$ Per Capita

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, % Of Gdp

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe